Synonym
AZD-3199; AZD 3199; AZD3199.
IUPAC/Chemical Name
N-(2-(diethylamino)ethyl)-N-(2-((2-(4-hydroxy-2-oxo-2,3-dihydrobenzo[d]thiazol-7-yl)ethyl)amino)ethyl)-3-(2-(naphthalen-1-yl)ethoxy)propanamide
InChi Key
ZVULMJYRVAVKCP-UHFFFAOYSA-N
InChi Code
InChI=1S/C32H42N4O4S/c1-3-35(4-2)20-21-36(19-18-33-17-14-26-12-13-28(37)30-31(26)41-32(39)34-30)29(38)16-23-40-22-15-25-10-7-9-24-8-5-6-11-27(24)25/h5-13,33,37H,3-4,14-23H2,1-2H3,(H,34,39)
SMILES Code
O=C(N(CCN(CC)CC)CCNCCC1=C(SC(N2)=O)C2=C(O)C=C1)CCOCCC3=C4C=CC=CC4=CC=C3
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS#
925243-19-2 (AZD-3199 Free)
925244-40-2 (AZD-3199 dihydrobromide)
Preparing Stock Solutions
The following data is based on the
product
molecular weight
578.77
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Bjermer L, Kuna P, Jorup C, Bengtsson T, Rosenborg J. Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting β2-adrenoreceptor agonist (uLABA). Drug Des Devel Ther. 2015 Feb 5;9:753-62. doi: 10.2147/DDDT.S66049. PubMed PMID: 25709399; PubMed Central PMCID: PMC4330041.
2: Bjermer L, Rosenborg J, Bengtsson T, Lötvall J. Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting β₂-adrenoceptor agonist, with formoterol in patients with asthma. Ther Adv Respir Dis. 2013 Oct;7(5):264-71. doi: 10.1177/1753465813497527. PubMed PMID: 23907810.
3: Kuna P, Ivanov Y, Trofimov VI, Saito T, Beckman O, Bengtsson T, Jorup C, Maltais F. Efficacy and safety of AZD3199 vs formoterol in COPD: a randomized, double-blind study. Respir Res. 2013 Jun 3;14:64. doi: 10.1186/1465-9921-14-64. PubMed PMID: 23731768; PubMed Central PMCID: PMC3691744.
4: Norman P. Which of three structures is AZD-3199? WO-2008104790, WO-2008096112 and WO-2008096119. Expert Opin Ther Pat. 2009 Aug;19(8):1157-63. doi: 10.1517/13543770902815527. PubMed PMID: 19563269.
